Literature DB >> 25501377

Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.

Keith C P Wu1, Zarif K Jabbar-Lopez2.   

Abstract

Omalizumab, an anti-IgE mAb, has recently been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of chronic idiopathic urticaria. Saini et al. (2014) (this issue) report on ASTERIA I, a 40-week randomized, double-blinded, placebo-controlled phase III trial evaluating omalizumab for the treatment of this disease.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25501377     DOI： 10.1038/jid.2014.362

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  6 in total

1.  IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies.

Authors:  D M Barrios; G S Phillips; A N Geisler; S R Trelles; A Markova; S J Noor; E A Quigley; H C Haliasos; A P Moy; A M Schram; J Bromberg; S A Funt; M H Voss; A Drilon; M D Hellmann; E A Comen; S Narala; A B Patel; M Wetzel; J Y Jung; D Y M Leung; M E Lacouture
Journal:  Ann Oncol       Date:  2021-03-03       Impact factor: 51.769

2.  Economic burden of refractory chronic spontaneous urticaria on Kuwait's health system.

Authors:  Mona Al-Ahmad; Maryam S Alowayesh; Norman V Carroll
Journal:  Clinicoecon Outcomes Res       Date:  2016-05-10

Review 3.  Dendritic Cell-Mediated Th2 Immunity and Immune Disorders.

Authors:  Sunil Kumar; Yideul Jeong; Muhammad Umer Ashraf; Yong-Soo Bae
Journal:  Int J Mol Sci       Date:  2019-05-01       Impact factor: 5.923

4.  Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic.

Authors:  Luciana Kase Tanno; Pascal Demoly; Bryan Martin; Jonathan Berstein; Mario Morais-Almeida; Michael Levin; Alessandro Fiocchi; Mario Sánchez-Borges; Luis R Caraballo; Gary Wong; José Antonio Ortega-Martell; Philip Rouadi; Anahí Yáñez; Liang Lu Wang; David B Peden; Manana Chikhladze; Sandra N González-Díaz; Jean-François Fontaine; James Sublett; Yoon-Seok Chang; Giovanni Passalacqua; Ignacio J Ansotegui; Motohiro Ebisawa; Gianenrico Senna; Marco Caminati
Journal:  World Allergy Organ J       Date:  2021-01-31       Impact factor: 4.084

5.  Acupoint injection of Bacillus Calmette-Guerin polysaccharide nucleic acid for patients with chronic urticaria: A protocol for systematic review.

Authors:  Wei Cao; Xianjun Xiao; Leixiao Zhang; Lu Wang; Qianhua Zheng; Siyuan Zhou; Ying Liu; Yue Cao; Mingling Chen; Chunxiao Li; Ying Li
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

6.  Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma-A Romanian Perspective.

Authors:  Elena Camelia Berghea; Mihaela Balgradean; Carmen Pavelescu; Catalin Gabriel Cirstoveanu; Claudia Lucia Toma; Marcela Daniela Ionescu; Roxana Silvia Bumbacea
Journal:  Children (Basel)       Date:  2021-12-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.